Travere Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M |
| Operating income | -$62.8M | -$323.8M | -$388.1M | -$319.8M | -$199.4M |
| Cost of revenue | $10.3M | $7.7M | $11.4M | $4.4M | $3.8M |
| Cash from operations | $37.8M | -$237.5M | -$280.0M | -$186.3M | -$14.8M |
| Capital expenditure | — | — | $668,000 | $191,000 | $5.1M |
| Free cash flow | — | — | -$280.7M | -$186.5M | -$19.9M |
| Impairments | $0 | $1.2M | $0 | $0 | $0 |
| Total assets | $605.2M | $594.1M | $788.9M | $672.6M | $776.6M |
| Total liabilities | $490.4M | $535.0M | $588.1M | $629.7M | $474.5M |
Shares outstanding 93.0M · Free float 92.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.